Since however, PYCR1 has recently been found to be upregulated in many cancer cells and to have tumour promoting effects both in cancer cells and CAFs (59, 111, 112), the development of new inhibitors may prove useful in targeting both tumour and stroma, killing two birds with one stone. This evidence concerns the gene PYCR1 and neoplasm.